Catch up with the latest happenings at Terremoto.
Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development.
Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer.
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round.
Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Terremoto Biosciences Appoints James Christensen, Ph.D., as President, Head of Research & Development
/in 2025, Press Release/by gmooreTerremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development.
Terremoto Biosciences Appoints Charles Baum, M.D., Ph.D., as Chief Executive Officer
/in 2024, Press Release/by gmooreTerremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer.
Terremoto Biosciences Closes $175 Million Series B Financing
/in 2023, Press Release/by David AndersonTerremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round.
Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines
/in 2022, Press Release/by eallisonTerremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.